ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...
What Is Doptelet, and Why Does It Matter? Doptelet (avatrombopag) is a prescription medicine that helps the body make more platelets (cells that help stop bleeding). First approved in 2018 for adults, ...
Please provide your email address to receive an email when new articles are posted on . Eltrombopag increased durable platelet response for children with newly diagnosed immune thrombocytopenia.
Early detection and innovative therapies are crucial for managing rare blood disorders like VITT, ITP, and hemophilia. Marstacimab's approval offers a new subcutaneous treatment option for hemophilia ...
Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that ...
The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.
The National Institute for Health and Care Excellence (NICE) yesterday issued final draft guidance recommending reimbursement for GlaxoSmithKline's Revolade (eltrombopag) for chronic immune ...
While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion five years ago, another one of the Bruton tyrosine kinase (BTK) inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results